1. Market Research
  2. > Pharmaceutical
  3. > Biopharmaceutical Market Trends
Cell Therapy Instruments Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product ; Cell Type ; Process ; End User, and Geography

Cell Therapy Instruments Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product ; Cell Type ; Process ; End User, and Geography

  • September 2020
  • 200 pages
  • ID: 5978058
  • Format: PDF
  • The Insight Partners
Up to $1700 off Until Jul 31st 2021


Table of Contents

Search Inside

The cell therapy market was valued at US$ 12,340.03 million in 2019 and is projected to reach US$ 32,477.15 million by 2027; it is expected to grow at a CAGR of 13.3% from 2020 to 2027.

The growth of the cell therapy instruments market is mainly attributed to the factors such as increasing developments in cell therapy manufacturing and rising number of approvals for cell-based therapies. On the other hand, high cost of cell therapy production and cell therapy are expected to hinder market growth.
The growing advancements in biotechnology have led to the introduction of personalized treatments for people suffering from various health conditions.For instance, stem cell and immune cell therapies are preferred to treat chronic diseases such as cancer, diabetes, neurological disorders, and genetic disorders.

Further, the cell therapy advantages, such as targeted treatment, faster and efficient recovery, and reduced side effectspromote the launch of various products in the market, thereby increasing the production volume.

In North America and Europe, cell therapies are widely adopted owing to the availability of the US Food and Drug Administration (FDA) approved products in the market.For instance, in April 2020, FDA awarded regenerative medicine advanced therapy (RMAT) designation to Novartis’ Kymriah (tisagenlecleucel) to treat refractory (r/r) follicular lymphoma (FL) in adults.

The company claims that the therapy has the potential to treat acute lymphoblastic leukemia (ALL) and r/r adult diffuses large B-cell lymphoma (DLBCL) in children and young adults.
Similarly, in October 2017, Kite, a Gilead, received an approval from FDA for its Yescarta, the first chimeric antigen receptor T cell (CAR T) therapy that treats refractory large B-cell lymphoma after two or more steps of systemic therapy in adults. In June 2020, the company announced the opening of a manufacturing hub in Amsterdam after it received an approval from the European Medicines Agency (EMA).
There are several ongoing clinical trials for cell therapies; thus, to commercialize cell therapy products to the masses, manufacturers need to increase their production capacity.Various market players such as ThermoFisher Scientific Inc, Cytiva, Danaher Corporation, and Lonza are offering laboratory instruments.

Also, the rising demand for cell therapies have attracted biotechnology startups to enter the cell therapy domain. Thus, various biopharmaceutical companies and startups have increased their production, which has eventually increased the demand for cell therapy instruments.

Based on product, the cell therapy instrumentmarket is segmented into the consumables, equipment, systems, and software.In 2019, the consumables segment accounted for the highest share of the market.

The growth of the segment is attributed to the rising research activities that demand reagents, kits, and lab wares in higher quantity.Also, the increased production for commercialization has influenced the market for the consumables segments.

Additionally, the rising adoption of cell therapy has increased the demand for storage consumables to supply and distribute it to the desired places.

Based on cell type, the cell therapy instrumentsmarket is segmented into human cells and animal cells.The human cells segment held a larger share of the market in 2019, and is estimated to register a higher CAGR in the market during the forecast period.

The growth of segment is determined to growing research based on human cells to derived personalized medicines as the genetic makeup of a patient, and growing product developments for the human cells.

Based on process, the cell therapy instrumentsmarket is segmented into cell processing, process monitoring and quality control, and cell preservation, distribution, and handling. The cell processing segment held the largest share of the market in 2019, and is estimated to register the highest CAGR in the market during the forecast period.

Based on end user, the cell therapy instruments market is segmented into research institutes, life science research companies, and other end users. The life science research companies segment held the largest share of the market in 2019, and same segment is estimated to register the highest CAGR of 14.0% in the market during the forecast period.

The Food and Drug Administration, European Medicines Agency, Italian Medicines Agency, The Global Burden of Disease Study, American Society of Gene & Cell Therapy, and Ministry of Health and Preventionare among the major secondary sources referred for preparing this report.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
20% Off


  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on